Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  CareDx, Inc    CDNA

CAREDX, INC

(CDNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

CareDx : Supports Bipartisan Legislation to Protect Kidney Transplant Patients

share with twitter share with LinkedIn share with facebook
share via e-mail
12/23/2019 | 02:39pm EDT

BRISBANE, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, applauds Congress on the introduction of bipartisan legislation in the House of Representatives that would extend Medicare coverage of immunosuppressive medications for kidney transplant recipients.

The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 5534) was introduced today in the House by Reps. Ron Kind (R-WI) and Michael Burgess, M.D. (R-TX). This bill will allow kidney transplant recipients to maintain Medicare Part B coverage for immunosuppressive medications beyond the current three-year limit, extending coverage for the lifetime of the transplanted kidney.

“The current Medicare reimbursement system for kidney patients’ post-transplant care makes no sense morally or financially. Despite the ‘Immuno Bill’ being introduced repeatedly for nearly two decades, Congress has yet to make the necessary changes,” said Peter Maag, CEO of CareDx. “Now that Congress, the community, and the administration are all aligned, it’s time to make sure this bill gets to the President’s desk for his signature. We look forward to working with congressional champions to make sure Medicare patients gifted with a kidney transplant never have to worry about rejection due to the inability to afford the necessary medications.”

CareDx is proud to support members of the kidney and transplant community who have been pushing for this monumental change for nearly two decades, including the American Association of Kidney Patients, the American Society of Nephrology, the American Society of Transplantation, the American Society of Transplant Surgeons, the National Kidney Foundation, and Transplant Recipients International Organization—among many others—and will continue its work to support efforts to pass this long-awaited policy change.

In line with its mission of improving the lives of organ transplant patients, CareDx has sponsored the Honor the Gift campaign—a national, patient-centered, grassroots movement promoted by a coalition of kidney and transplant organizations to advocate for the extension of immunosuppression medication coverage for kidney transplant patients. Learn more about the Honor the Gift at HonorTheGift.org.

Reps. Anna Eshoo (D-CA), Jason Smith (R-MO), Donald McEachin (D-VA), and Jamie Herrera Beutler (R-WA) joined Burgess and Kind in the House of Representatives as original co-sponsors of the legislation.

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.

For more information, please visit: www.CareDx.com.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com 

Investor Relations
Greg Chodaczek
646-924-1769
investor@caredx.com 

CareDx logo.jpg

Source: CareDx, Inc.

2019 GlobeNewswire, Inc., source Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on CAREDX, INC
03/20REPEAT - NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted Af..
GL
03/20NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted After Anti-..
AQ
03/20NEW AJT PUBLICATION : AlloSure Monitors First Patient Retransplanted After Anti-..
GL
03/17CAREDX LAUNCHES REMOTRAC : Home-Based Monitoring of Transplant Patients
GL
03/12CareDx Joins National Kidney Foundation on World Kidney Day to Support Kidney..
GL
03/05CareDx Brings Personalized Care to Transplant with the Launch of KIRA Immuno-..
GL
02/28CareDx to Participate in Upcoming Investor Conferences
GL
02/28CAREDX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
AQ
02/27CAREDX : 4Q Earnings Snapshot
AQ
02/27CAREDX, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
More news
Financials (USD)
Sales 2020 167 M
EBIT 2020 -21,6 M
Net income 2020 -20,1 M
Debt 2020 -
Yield 2020 -
P/E ratio 2020 -51,7x
P/E ratio 2021 937x
Capi. / Sales2020 5,60x
Capi. / Sales2021 4,32x
Capitalization 937 M
Chart CAREDX, INC
Duration : Period :
CareDx, Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CAREDX, INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 45,00  $
Last Close Price 21,85  $
Spread / Highest target 170%
Spread / Average Target 106%
Spread / Lowest Target 60,2%
EPS Revisions
Managers
NameTitle
Peter K. Maag Chairman & Chief Executive Officer
Reginald Seeto President & Chief Business Officer
Paul Ciccolella Senior Vice President-Global Operations
Michael Bell Chief Financial & Principal Accounting Officer
Robert N. Woodward Vice President-Research & Development
Sector and Competitors